FindTrial
Sign In

The role of 18F-FDG PET/CT in multiple myeloma staging and restaging according to IMPeTUs: comparison of the Durie-Salmon Plus and other staging systems

The role of 18F-FDG PET/CT in multiple myeloma staging and restaging according to IMPeTUs: comparison of the Durie-Salmon Plus and other staging systems

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015093
Enrollment
Unknown
Registered
2018-03-07
Start date
2018-03-13
Completion date
Unknown
Last updated
2018-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

Gold Standard:Durie-Salmon Plus, hematological test
Index test:18F-FDG PET/CT

Sponsors

The First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
34 Years to 77 Years

Inclusion criteria

Inclusion criteria: 1) the diagnosis of MM confirmed by the presence of an M-component in serum and/or urine plus clonal plasma cells in the bone marrow and/or a documented clonal plasmacytoma; 2) digital image data available for retrospective analysis; 3) time interval between assessment of hematological and immunologic parameters and 18F-FDG PET/CT <3 weeks.

Exclusion criteria

Exclusion criteria: 1) insufficient information for RISS, DSS and DS Plus; 2) MM patients who had additional diseases.

Design outcomes

Primary

MeasureTime frame
SUV;—

Countries

China

Contacts

Public ContactBin Zhang

The First Affiliated Hospital of Soochow University

zbnuclmd@126.com+86 13915519962

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026